In patients with advanced solid tumors, tivantinib combined with sorafenib treatment was shown to be safe, especially for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and melanoma patients harboring tumors with high levels of c-Met; an enhanced therapeutic effect was also observed for these cases. This evidence concerns the gene MET and renal cell carcinoma.